
Clinical Neuroscience | |
Name | Pei-Ning Wang |
pnwang@vghtpe.gov.tw | |
POSITION TITLE/AFFILIATIONS | Professor/ Department of Neurology, School of Medicine, National Yang-Ming University Attending Physicision/ Department of Neurology, Taipei Veterans General Hospital |
EDUCATION/TRAINING | 1983-1990 MedicineMD, National Yang-Ming University, Taipei, Taiwan 1992-1997 Resident in Neurology, Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan 2003-2004 Behavior Neurology FellowshipMemory and Aging Center, University of California, San Francisco, USA |
Research | The biomarkers of dementia, especially Alzheimer disease (AD) in Taiwan |
研究概況 | My research is focus on investigating the biomarkers of dementia, especially Alzheimer disease (AD) in Taiwan. In the earlier years, we made efforts on establish the validity of the Chinese-version neuropsychological tests to make a accurate early diagnosis of mild AD and mild cognitive impairment (MCI). We published the presentations of verbal memory, executive function, language functions and daily functions in MCI and mild AD. Recently, we cooperated with experts in genetics, pharmacology, biochemistry, and neuroimaging for extending our research to the bio-molecular and neuroimaging aspects of dementia. As PI or co-Investigator on several national and hospital funded grants, I laid the groundwork for the proposed research by investigating biomarkers for early diagnosis of Alzheimer’s disease and prediction the progress from aging to mild cognitive impairment and dementia. We found the rate of hippocampal atrophy was note only higher in progressive MCI, but also in stable MCI. Longitudinally evaluating hippocampal volume may be more sensitive than neuropsychological tests to detect the progression of MCI. Last year, we published the special patterns of axonal degeneration and myelin degradation in different brain regions in MCI and mild AD. In the next few years, our research focus will be placed on inspecting the trajectory of different biomarkers from preclinical AD, MCI due to AD, to dementia due to AD. |